Catalogo dei Corsi di studio

Francesco Fazi, Ph.D
ADDRESS: Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology and Medical Embryology, Sapienza University of Rome, Via A. Scarpa, 14-16, 00161 Rome, Italy; Telephone 06-49766575; Fax 06-4462854; E-mail francesco.fazi@uniroma1.it

EDUCATION:
1998: Degree in Biology, with honors, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, with a dissertation entitled: Molecular and Genetic Alteration of Acute Myeloid Leukemia .
2003: Ph.D. degree in Morphogenetic and Cytological Science, Department of Histology and Medical Embryology, Sapienza University of Rome, with a dissertation entitled: Molecular Basis for Transcriptional Differentiation Therapy of Acute Myeloid Leukemia .

SCIENTIFIC EXPERIENCE:
1999-2003: Ph.D. program in Morphogenetic and Cytological Science. Department of Histology and Medical Embryology, Sapienza University of Rome, Rome, Italy.
2000-01: Ph.D. student, laboratory of Prof. Pier Giuseppe Pelicci, European Institute of Oncology, Milan, Italy.
2004-07: Post-doctoral Fellow with a project entitled: Characterization of the biological role of the remodeling chromatin agents on normal and leukemic hematopoietic progenitors , Department of Histology and Medical Embryology, Sapienza University of Rome, Rome, Italy.
2007: University Researcher. Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy.
2018: Associate Professor of Histology and Human Embryology SSD BIO/17. Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy.
2019: National Scientific Qualifications as Full Professor in SSD BIO/17 Histology.

TEACHING AND INSTITUTIONAL ACTIVITIES:
2003-to date: Teacher in the Integrated Course of Histology and Embryology, School of Medicine CLM "E" -Polo Pontino- Sapienza University of Rome.
2008-to date: Teacher of Histology in the Integrated Course of Anatomy, Histology and Physiology of the Degree Course in Biomedical Laboratory Techniques "C" -Polo Pontino- Sapienza University of Rome.
2008-to date: Teacher at the PhD School in Morphogenesis and Tissue Engineering, Sapienza University of Rome.
2020-to date: Coordinator and Teacher in the Integrated Course of Histology and Embryology, School of Medicine CLM "HT" - Sapienza University of Rome.
2020-to date: President of the Degree Course in Biomedical Laboratory Techniques "C" -Polo Pontino- Sapienza University of Rome.

2019-to date: Junior Research Fellow - Sapienza School for Advanced Studies (SSAS)
2014-2015 and 2019-2020: Member of the Research Committee of Sapienza University of Rome.

ACADEMIC AWARDS:
2003: Ph.D. degree award for the doctoral dissertation assigned by the Italian Cell Biology and Differentiation Association, Italy.
2008: Silvia Fiocco" award for young investigator involved in researcher on leukemia and lymphoma assigned by National Academy of Lincei, Italy.

SOCIETY MEMBERBERSHIPS:
2007- to date: Member of the College of Teachers of Histology and Embryology;
2012- to date: Member of the Medical Academy of Rome;
2013- to date: Member of the Italian Society of Anatomy and Histology;
2018- to date: Member of the Italian Society of Experimental Hematology (SIES);
2019- to date: Member of the Italian Society of Histochemistry (SII);
2019- to date: Membrer of Association of Cell Biology and Differentiation (ABCD)

CONTRIBUTION TO SCIENTIFIC CONFERENCES (selected list):
- Invited speaker. "Role of microRNAs and the RISC complex in pathological hematopoiesis" as part of the THEME DAY on "MicroRNAs: from the state of the art to therapeutic perspectives", held in Rome at the Medical Academy of Rome - on March 29, 2012;
- Invited speaker. Lecture "MicroRNA pathways as new functional axes in cell fate determination" at the 67th National Congress of the Italian Society of Anatomy and Histology (SIAI), held in Brescia from 20 to 22 September 2013
-Selected speaker. "Argonaute 2 contribution to the gene expression program driving human myeloid differentiation of Acute Myeloid Leukemia cells" as part of the 6th International Symposium on Acute Promyelocytic Leukemia, held in Rome from 29 September to 2 October 2013;
- Organization and moderation of the Non-coding RNA symposium during the XVI Congress of the Italian Life Sciences Foundation (FISV) held in Rome from 20 to 23 September 2016;
- Organization and moderation of the THEME DAY entitled "Epitrascriptomics: a new revolution in the world of RNA with a role in cell development and neoplastic transformation" held in Rome at the Medical Academy of Rome on 23 May 2019;

MEMBER OF EDITORIAL BOARDS:
2013: Guest Editor for MicroRNA Journal, - Bentham Science - for the Thematic Issue entitled: MicroRNAs: Non-Coding Pleiotropic Factors in Development, Cancer Prevention and Treatment , MicroRNA. 2013;2(2):81.
2019: Guest Topic Editor for the Research Topic entitled The RNA Revolution in Embryonic Development and Cell Differentiation in Health and Disease in the Stem Cell Research section of Frontiers Cell and Developmental Biology.
2021: Guest Topic Editor for the Research Topic entitled Protein Homeostasis in Growth, Development and Disease in the Signaling section of Frontiers Cell and Developmental Biology.

REVIEWER FOR SCIENTIFIC JOURNALS AND NATIONAL AND INTERNATIONAL FUNDING AGENCIES:
- Reviewer for several International Scientific Journals as: Blood, Leukemia, Oncogene, Cell Death and Differentiation, Cell Death and Disease, Cancer Research, Frontiers in Oncology.
- Reviewer for National and International Founding Agencies as: the Bloodwise UK Foundation, UK (February 2016); the National Science Center, Poland (April 2016); Regina Elena National Cancer Institute, Italy (Ricerca Finalizzata 2010-2011).

ACTIVITY IN NATIONAL AND INTERNATIONAL RESEARCH INSITUTES:
- European Institute of Oncology - IEO - Milan, laboratory of Molecular Mechanisms of Cancer headed by Prof. Pier Giuseppe Pelicci, during PhD program (period 09/2000 - 12/2000);
- San Raffaele Bio-Medical Park Foundation of Rome, laboratory of Neoplastic cell Differentiation headed by Prof.ssa Clara Nervi (period 2002-2010);

RESEARCH GRANTS (selected list):
- Project AIRC-NUSUG 2007-2012 (New Unit Start-Up Grant) dell'Associazione Italiana per la Ricerca sul Cancro (AIRC) entitled: "Regolazione trascrizionale e caratterizzazione funzionale dei microRNAs nell'ematopoiesi patologica". Months: 60; role: Responsabile Scientifico;
- Project Ateneo 2012 - Sapienza Università di Roma entitled: "Identificazione e caratterizzazione dei microRNA come marcatori terapeutici innovativi per i tumori umani del tessuto epiteliale timico . Months: 12; role: Responsabile Scientifico;
- Project Ateneo 2016 - Sapienza Università di Roma entitled: Epigenetic regulation and functional characterization of miR- 145-5p in thymic epithelial tumors . Months: 12; role: Responsabile Scientifico;
- PRIN 2017: Modulation of EGFR signalling by cross-talk with other membrane receptor pathways . Months: 36 role: Responsabile di Unità di Ricerca.
- Project Fondazione Cenci-Bolognetti Call 2018 Under 45 entitled: Development of a combination strategy based on ER and oxidative stress in Acute Myeloid Leukemia . Months: 24; role: Responsabile Scientifico;
- Project Ateneo 2018 - Sapienza Università di Roma entitled: Impact of circulating miRNAs uptake and internalization on of EGFR signaling pathway in neoplastic cells . Months: 12; role: Responsabile Scientifico;
- Project AIRC 2018: Development of a therapeutic strategy based on ER and oxidative stress to target Acute Myeloid Leukemia . Months: 60 role: Responsabile Scientifico;
- Project Ateneo 2021 - Sapienza Università di Roma entitled: Development of novel therapeutic strategies to overcome resistance to tyrosine-kinase and bcl-2 inhibitors in FLT3-ITD+ Acute Myeloid Leukemia cells. . Months: 12; role: Responsabile Scientifico;

PATENTS:
Inventor in Patent (N. 102020000001732), concerning the COMPOSITION FOR USE IN THE TREATMENT OF LEUKEMIA released 01/02/2022

PERSONAL SKILLS AND COMPETENCES: Francesco Fazi has a long experience in the field of molecular mechanisms regulating growth and differentiation on a variety of normal and neoplastic cell systems and has been involved in studies showing novel oncogenic mechanisms for the leukemia-associated fusion proteins and the role of epigenetic mechanisms in the differentiation block and therapy response of Acute Myeloid Leukemia. Francesco Fazi is currently involved in different multidisciplinary collaborations investigating the epigenetic and epitranscriptomic regulation and the functional characterization of different non-coding RNA in normal and pathological cell fate determination.

CITATIONS IN INTERNATIONAL JOURNALS:
To date, the research papers of Prof. Fazi gained over 4.450 citations in peer-reviewed international journals, and he currently holds an H-index of 29 (Scopus).

Publications

1. Palombarini F, Masciarelli S, Incocciati A, Liccardo F, Di Fabio E, Iazzetti A, Fabrizi G, Fazi F, Macone A, Bonamore A, Boffi A. Self-assembling ferritin-dendrimer nanoparticles for targeted delivery of nucleic acids to myeloid leukemia cells. J Nanobiotechnology. 2021 Jun 9;19(1):172.
2. Fazi F, Fatica A. Regulation of Ribosome Function by RNA Modifications in Hematopoietic Development and Leukemia: It Is Not Only a Matter of m6A. Int J Mol Sci. 2021 Apr 30;22(9):4755.
3. Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resist Updat. 2021 Jan; 54:100742.
4. Ceci M, Fazi F, Romano N. The role of RNA-binding and ribosomal proteins as specific RNA translation regulators in cellular differentiation and carcinogenesis. Biochim Biophys Acta Mol Basis Dis. 2021 Apr 1;1867(4):166046.
5. Tito C, Ganci F, Sacconi A, Masciarelli S, Fontemaggi G, Pulito C, Gallo E, Laquintana V, Iaiza A, De Angelis L, Benedetti A, Cacciotti J, Miglietta S, Bellenghi M, Carè A, Fatica A, Diso D, Anile M, Petrozza V, Facciolo F, Alessandrini G, Pescarmona E, Venuta F, Marino M, Blandino G, Fazi F. LINC00174 is a novel prognostic factor in Thymic Epithelial Tumors involved in cell migration and lipid metabolism. Cell Death Dis. 2020. Cell Death Dis. 2020 Nov 7;11(11):959.
6. Melis E, Gallo E, di Martino S, Gallina FT, Laquintana V, Casini B, Visca P, Ganci F, Alessandrini G, Caterino M, Cecere FL, Mandoj C, Papadantonakis A, De Bello N, Lattanzio R, Palmieri G, Garassino MC, Girard N, Conti L, Blandino G, Fazi F, Facciolo F, Pescarmona E, Ciliberto G, Marino M. Thymic Epithelial Tumors as a Model of Networking: Development of a Synergistic Strategy for Clinical and Translational Research Purposes. Front Oncol. 2020 Jul 14;10:922.
7. Genovese I, Giamogante F, Barazzuol L, Battista T, Fiorillo A, Vicario M, D'Alessandro G, Cipriani R, Limatola C, Rossi D, Sorrentino V, Poser E, Mosca L, Squitieri F, Perluigi M, Arena A, van Petegem F, Tito C, Fazi F, Giorgi C, Calì T, Ilari A, Colotti G. Sorcin is an early marker of neurodegeneration, Ca2+ dysregulation and endoplasmic reticulum stress associated to neurodegenerative diseases. Cell Death Dis. 2020 Oct 15;11(10):861.
8. Banella C, Catalano G, Travaglini S, Divona M, Masciarelli S, Guerrera G, Fazi F, Lo Coco F, Voso MT, Noguera N. PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells. Cancers (Basel). 2020 Jan; 12(1): 95. doi: 10.3390/cancers12010095.
9. Di Agostino S, Riccioli A, De Cesaris P, Fontemaggi G, Blandino G, Filippini A, Fazi F. Circular RNAs in embryogenesis and cell differentiation with a focus on cancer development. Front Cell Dev Biol. 2020 May 27;8: 389.
10. Donzelli S, Sacconi A, Turco C, Gallo E, Milano E, Iosue I, Blandino G°, Fazi F°, Fontemaggi G°. Paracrine Signaling from Breast Cancer Cells Causes Activation of ID4 Expression in Tumor-Associated Macrophages. Cells. 2020 Feb 11;9(2). pii: E418. doi: 10.3390/cells9020418.
11. Petrozza V, Costantini M, Tito C, Giammusso LM, Sorrentino V, Cacciotti J, Porta N, Iaiza A, Pastore AL, Di Carlo A, Simone G, Carbone A, Gallucci M, Fazi F. Emerging role of secreted miR-210-3p as potential biomarker for clear cell Renal Cell Carcinoma metastasis. Cancer Biomark. 2020;27(2):181-188. doi: 10.3233/CBM-190242.
12. Müller M, Fazi F, Ciaudo C. Argonaute Proteins: From Structure to Function in Development and Pathological Cell Fate Determination. Front Cell Dev Biol. 2020 Jan 22; 7:360. doi: 10.3389/fcell.2019.00360. Review.
13. Macone A, Masciarelli S, Palombarini F, Quaglio D, Boffi A, Trabuco MC, Baiocco P, Fazi F, Bonamore A. Ferritin nanovehicle for targeted delivery of cytochrome C to cancer cells. Sci Rep. 2019 Aug 13;9(1):11749. doi: 10.1038/s41598-019-48037-z.
14. Fazi F, Fatica A. Interplay Between N 6-Methyladenosine (m6A) and Non-coding RNAs in Cell Development and Cancer. Front Cell Dev Biol. 2019 Jun 28; 7:116. doi: 10.3389/fcell.2019.00116.. Review.
15. Masciarelli S, Capuano E, Ottone T, Divona M, Lavorgna S, Liccardo F, niegocka M, Travaglini S, Noguera NI, Picardi A, Petrozza V, Fatica A, Tamagnone L, Voso MT, Lo Coco F, Fazi F. Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML. Blood Adv. 2019 Dec 23;3(24):4155-4160. doi: 10.1182/bloodadvances.2019000540.
16. Bellissimo T, Tito C, Ganci F, Sacconi A, Masciarelli S, Di Martino G, Porta N, Cirenza M, Sorci M, De Angelis L, Rosa P, Calogero A, Fatica A, Petrozza V, Fontemaggi G, Blandino G, Fazi F. Argonaute 2 drives miR-145-5p-dependent gene expression program in breast cancer cells. Cell Death Dis. 2019 Jan 8;10(1):17. doi: 10.1038/s41419-018-1267-5.
17. Donzelli S, Milano E, Pruszko M, Sacconi A, Masciarelli S, Iosue I, Melucci E, Gallo E, Terrenato I, Mottolese M, Zylicz M, Zylicz A, Fazi F°, Blandino G°, Fontemaggi G°. Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages. Breast Cancer Res. 2018 Jun 19;20(1):59. doi: 10.1186/s13058-018-0990-2.
18. Masciarelli S, Capuano E, Ottone T, Divona M, De Panfilis S, Banella C, Noguera NI, Picardi A, Fontemaggi G, Blandino G, Lo-Coco F, Fazi F. Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress. Leukemia. 2018 Feb;32(2):285-294. doi: 10.1038/leu.2017.231.
19. Sorci M, Ianniello Z, Cruciani S, Larivera S, Ginistrelli LC, Capuano E, Marchioni M, Fazi F, Fatica A. METTL3 regulates WTAP protein homeostasis. Cell Death Dis. 2018 Jul 23;9(8):796. doi: 10.1038/s41419-018-0843-z.
20. Falvo E, Malagrinò F, Arcovito A, Fazi F, Colotti G, Tremante E, Di Micco P, Braca A, Opri R, Giuffrè A, Fracasso G, Ceci P. The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity. J Control Release. 2018 Apr 10;275:177-185. doi: 10.1016/j.jconrel.2018.02.025.
21. Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Updat. 2017 May; 32:23-46. doi: 10.1016/j.drup.2017.10.003. Epub 2017 Oct 16. Review.
22. Pruszko M, Milano E, Forcato M, Donzelli S, Ganci F, Di Agostino S, De Panfilis S, Fazi F, Bates DO, Bicciato S, Zylicz M, Zylicz A, Blandino G, Fontemaggi G. The mutant p53-ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO Rep. 2017 Jun 26. pii: e201643370. doi: 10.15252/embr.201643370.
23. Bellissimo T, Ganci F, Gallo E, Sacconi A, Tito C, De Angelis L, Pulito C, Masciarelli S, Diso D, Anile M, Petrozza V, Giangaspero F, Pescarmona E, Facciolo F, Venuta F, Marino M, Blandino G, Fazi F. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation. Mol Cancer. 2017 May 10;16(1):88. doi: 10.1186/s12943-017-0655-2.
24. Petrozza V, Pastore AL, Palleschi G, Tito C, Porta N, Ricci S, Marigliano C, Costantini M, Simone G, Di Carlo A, Gallucci M, Carbone A, Fazi F. Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma. Oncotarget. 2017 Jun 13, doi: 10.18632/oncotarget.18449.
25. Genovese I, Fiorillo A, Ilari A, Masciarelli S, Fazi F°, Colotti G°. Binding of doxorubicin to Sorcin impairs cell death and increases drug resistance in cancer cells. Cell Death Dis. 2017 Jul 20;8(7): e2950. doi: 10.1038/cddis.2017.342.
26. Bellissimo T, Russo E, Ganci F, Vico C, Sacconi A, Longo F, Vitolo D, Anile M, Disio D, Marino M, Blandino G, Venuta F, Fazi F. Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. Cancer Biol Ther. 2016; 17(1): 79-82.
27. Mangiavacchi A, Sorci M, Masciarelli S, Larivera S, Legnini I, Iosue I, Bozzoni I, Fazi F, Fatica A. The miR-223 host non-coding transcript linc-223 induces IRF4 expression in acute myeloid leukemia by acting as a competing endogenous RNA. Oncotarget. 2016 Sep 13;7(37):60155-60168. doi: 10.18632/oncotarget.11165.
28. Fracasso G, Falvo E, Colotti G, Fazi F, Ingegnere T, Amalfitano A, Doglietto GB, Alfieri S, Boffi A, Morea V, Conti G, Tremante E, Giacomini P, Arcovito A, Ceci P. Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness. J Control Release. 2016; 239:10-18.
29. Smeriglio P, Alonso-Martin S, Masciarelli S, Madaro L, Iosue I, Marrocco V, Relaix F, Fazi F, Marazzi G, Sassoon DA, Bouché M. Phosphotyrosine phosphatase inhibitor bisperoxovanadium endows myogenic cells with enhanced muscle stem cell functions via epigenetic modulation of Sca-1 and Pw1 promoters FASEB J. 2016; 30(4): 1404-15.
30. Fontemaggi G, Bellissimo T, Donzelli S, Iosue I, Benassi B, Bellotti G, Blandino G, Fazi F. Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition. RNA Biol. 2015; 12(7): 690-700.
31. Petrozza V, Carbone A, Bellissimo T, Porta N, Palleschi G, Pastore AL, Di Carlo A, Della Rocca C, Fazi F. Oncogenic MicroRNAs Characterization in Clear Cell Renal Cell Carcinoma. Int J Mol Sci. 2015; 16(12): 29219-25.
32. Hughes JM, Legnini I, Salvatori B, Masciarelli S, Marchioni M, Fazi F, Morlando M, Bozzoni I, Fatica A. C/EBP -p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia. Oncotarget. 2015; 6(21): 18534-44.
33. Venneri MA, Giannetta E, Panio G, De Gaetano R, Gianfrilli D, Pofi R, Masciarelli S, Fazi F, Pellegrini M, Lenzi A, Naro F, Isidori AM. Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic Mice. PLoS One. 2015; 10(5): e0126580.
34. Masciarelli S, Quaranta R, Iosue I, Colotti G, Padula F, Varchi G, Fazi F, Del Rio A. A small-molecule targeting the microRNA binding domain of argonaute 2 improves the retinoic acid differentiation response of the acute promyelocytic leukemia cell line NB4. ACS Chem Biol. 2014 Aug 15;9(8):1674-9. doi: 10.1021/cb500286b.
35. Ganci F, Vico C, Korita E, Sacconi A, Gallo E, Mori F, Cambria A, Russo E, Anile M, Vitolo D, Pescarmona E, Blandino R, Facciolo F, Venuta F, Blandino G, Marino M, Fazi F. MicroRNA expression profiling of thymic epithelial tumors. Lung Cancer. 2014 Aug;85(2):197-204. doi: 10.1016/j.lungcan.2014.04.008.
36. Blandino G, Fazi F, Donzelli S, Kedmi M, Sas-Chen A, Muti P, Strano S, Yarden Y. Tumor suppressor microRNAs: a novel non-coding alliance against cancer. FEBS Lett. 2014; 588(16): 2639-52. Review.
37. Vian L, Di Carlo M, Pelosi E, Fazi F, Santoro S, Cerio AM, Boe A, Rotilio V, Billi M, Racanicchi S, Testa U, Grignani F, Nervi C. Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors. Cell Death Differ. 2014; 21(2): 290-301.
38. Iosue I, Quaranta R, Masciarelli S, Fontemaggi G, Batassa EM, Bertolami C, Ottone T, Divona M, Salvatori B, Padula F, Fatica A, Lo-Coco F, Nervi C, Fazi F. Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells. Cell Death Dis. 2013 Nov 21;4:e926. doi: 10.1038/cddis.2013.452.
39. De Santa F, Iosue I, Del Rio A, Fazi F. MicroRNA biogenesis pathway as therapeutic target for human disease and cancer. Current Pharmaceutical Design 2013; 19(4): 745-64. Review.
40. Fatica A, Fazi F. MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune. Int J Mol Sci. 2013; 14(10): 20930-53. Review.
41. Salvatori B, Iosue I, Mangiavacchi A, Loddo G, Padula F, Chiaretti S, Peragine N, Bozzoni I, Fazi F, Fatica A. The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. Cell Death Dis. 2012 Oct 25;3:e413. doi: 10.1038/cddis.2012.151.
42. Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, Lo-Coco F. MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. J Hematol Oncol. 2012; 5: 26.
43. Fazi F, Fontemaggi G. MicroRNAs and lymph node metastatic disease in lung cancer. Thorac Surg Clin. 2012 May;22(2):167-75. doi: 10.1016/j.thorsurg.2011.11.001. Epub 2011 Dec 27. Review.
44. Zardo G, Ciolfi A, Vian L, Starnes LM, Billi M, Racanicchi S, Maresca C, Fazi F, Travaglini L, Noguera N, Mancini M, Nanni M, Cimino G, Lo-Coco F, Grignani F, Nervi C. Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood 2012; 119(17): 4034-46.
45. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2012;19(6): 1038-48.
46. Salvatori B., Iosue I., Djodji Damas N., Mangiavacchi A., Chiaretti S., Messina M., Padula F., Guarini A., Bozzoni I., Fazi F. and Fatica A. Critical role of c-Myc in Acute Myeloid Leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2. Genes & Cancer 2011; 2(5): 585-92.
47. Fontemaggi G., Dell'Orso S., Trisciuoglio D., Shay T., Melucci E., Fazi F., Terrenato I., Mottolese M., Muti P., Domany E., Del Bufalo D., Strano S., Blandino G. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol. 2009 Oct; 16(10): 1086-93.
48. Morey L., Brenner C., Fazi F., Villa R., Gutierrez A., Buschbeck M., Nervi C., Minucci S., Fuks F., Di Croce L. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol. 2008 Oct; 28(19): 5912-23.
49. Fazi F., Nervi C. MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovasc Res. 2008 Sep 1; 1; 79(4): 553-61.
50. Nervi C., Fazi F., Grignani F. Oncoproteins, heterochromatin silencing and microRNAs: a new link for leukemogenesis. Epigenetics 2008 Jan-Feb; 3(1): 1-4.
51. Fazi F., Racanicchi S., Zardo G., Starnes LM., Mancini M., Travaglini L., Diverio D., Ammatuna E., Cimino G., Lo-Coco F., Grignani F., Nervi C. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 2007 Nov; 12(5): 457-66.
52. Fazi F., Zardo G., Gelmetti V., Travaglini L., Ciolfi A., Di Croce L., Rosa A., Bozzoni I., Grignani F., Lo Coco F., Pelicci PG., Nervi C. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood 2007 May 15; 109(10): 4432-40.
53. Nervi C., Fazi F., Rosa A., Fatica A., Bozzoni I. Emerging role for microRNAs in acute promyelocitic leucemia. Curr Top Microbiol Immunol. 2007; 313: 73-84.
54. Fatica A., Rosa A., Fazi F., Ballarino M., Morlando M., De Angelis FG., Caffarelli E, Nervi C., Bozzoni I. MicroRNA and Hematopoietic Differentiation. Cold Spring Harb Symp Quant Biol. 2006; 71: 205-10.
55. Cimino G., Lo-Coco F., Fenu S., Travaglini L., Finolezzi E., Mancini M., Nanni M., Careddu A., Fazi F., Padula F., Fiorini R., Aloe Spiriti MA., Petti MC., Venditti A., Amadori S., Mandelli F., Pelicci PG. and Nervi C. Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. Cancer Research 2006 Sep 1; 66 (17): 8903-11;
56. Fazi F., Rosa A., Fatica A., Gelmetti V., De Marchis M.L., Nervi C., Bozzoni I. A mini-circuitry comprising microRNA-223 and transcription factors NFI-A and C/EBP regulates human granulopoiesis. Cell 2005 Dec 2; 123 (5): 819-31. IF 2005: 29.43; Citations: 726
57. Zardo G., Fazi F., Travaglini L., Nervi C. Dynamic and reversibility of heterocromatic gene silencing in human disease. Cell Research 2005 Sep; 15 (9): 679-90.
58. Fazi F., Travaglini L., Carotti D., Palitti F., Diverio D., Alcalay M., McNamara S., Miller W.H.Jr, Lo Coco F., Pelicci P.G., Nervi C. Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene 2005 Mar 10; 24 (11): 1820-30.
59. Petti M.C, Fazi. F., Gentile M., Diverio D., De Fabritiis P., De Propris M.S., Fiorini R., Spiriti M.A., Padula F., Pelicci P.G., Nervi C., Lo Coco F. Complete remission through blast cell differentiation in PLZF/RAR -positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 2002 Aug 1; 100(3): 1065-7.
60. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Lo Coco F., Kouzarides T., Nervi C., Minucci S., Pelicci P.G. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002 Feb 8; 295(5557): 1079-82.
61. Montefusco E., Fazi F., Cordone I., Ariola C., Nanni M., Spadea A., Aloe Spiriti M.A., Fenu S., Mandelli F., Petti M.C. Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma. Leukemia and Lymphoma 2001 Feb; 40 (5-6): 671-4.
62. Nervi C., Borello U., Fazi F., Buffa V., Pelicci P.G., Cossu G. Inhibition of histone deacetylation activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Research 2001 Feb 15; 61 (4): 1247-9
63. Ferrara F.F.#, Fazi F.#, Bianchini A., Padula F., Gelmetti V., Minucci S., Mancini M., Pelicci P.G., Lo Coco F., Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Research 2001 Jan 1; 61 (1): 2-7.
64. Mancini M., Cedrone M., Diverio D., Emanuel B., Stul M., Vranckx H., Brama M., De Cuia M.R., Nanni M., Fazi F., Mecucci C., Alimena G. and Hagemeijer A. Use of dual color interphase FISH for the detection of inv (16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patientes. Leukemia 2000 Mar; 14 (3): 364-8;

CHAPTERS IN TEXTBOOKS:
1. Boitani C, Dupont S, Fazi F, Nervi C. (2018). Struttura della Cellula: Nucleo e Ciclo Cellulare. Capitolo 3 - Istologia - VII Edizione - Piccin;
2. Nervi C, Fazi F. (2018). Il Sangue e la Linfa. Capitolo 20 - Istologia - VII Edizione - Piccin;
3. Fontemaggi G, Fazi F. (2016). Meccanismi molecolari delle neoplasie polmonari. In: Venuta F Coloni GF. Malattie del Torace - IV Edizione -. p. 555-572, Società Editrice Universo, ISBN: 978886515134;
4. Fontemaggi G., Fazi F. (2011). Le basi molecolari della cancerogenesi nel cancro del polmone. In: Venuta F - Coloni GF. Malattie del Torace - III Edizione - p. 549-566, Società Editrice Universo, ISBN: 9788865150245;